|
|
| Product Name: | LAH-1 | | Synonyms: | LAH-1;3-Pyridazinecarboxamide, N-[3-fluoro-4-[[2-[[(3-hydroxy-1-azetidinyl)carbonyl]amino]-4-pyridinyl]oxy]phenyl]-1-(4-fluorophenyl)-1,6-dihydro-4-methyl-6-oxo- | | CAS: | 3018150-68-7 | | MF: | C27H22F2N6O5 | | MW: | 548.5 | | EINECS: | | | Product Categories: | | | Mol File: | 3018150-68-7.mol |  |
| | LAH-1 Chemical Properties |
| density | 1.50±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted) | | pka | 9.00±0.70(predicted) |
| | LAH-1 Usage And Synthesis |
| Uses | LAH-1 is a c-Met inhibitor with oral activity and membrane permeability with an IC50 of 49 nM. LAH-1 has anticancer activity and can induce apoptosis, migration, and invasion[1]. | | References | [1] Sima L,et al. Discovery of LAH-1 as potent c-Met inhibitor for the treatment of non-small cell lung cancer[J]. Journal of Enzyme Inhibition and Medicinal Chemistry, 2024, 39(1): 2286435. DOI:10.1080/14756366.2023.2286435 |
| | LAH-1 Preparation Products And Raw materials |
|